<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">109</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2015-14-3-34-38</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ACUTE LEUKEMIA</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОСТРЫЙ ЛЕЙКОЗ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Clinical significance of methylenetetrahydrofolate reductase gene polymorphism in children with acute lymphoblastic leukemia receiving protocol therapy</article-title><trans-title-group xml:lang="ru"><trans-title>Клиническое значение полиморфизма гена метилентетрагидрофолатредуктазы у детей с острым лимфобластным лейкозом при проведении программной терапии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petina</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Петина</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>o.vpetina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Zborovskaya</surname><given-names>A. A.</given-names></name><name xml:lang="ru"><surname>Зборовская</surname><given-names>А. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>zborovskaa@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Matevosyan</surname><given-names>M. L.</given-names></name><name xml:lang="ru"><surname>Матевосян</surname><given-names>М. Л.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mariam@algimed.by</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Savitskaya</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Савицкая</surname><given-names>Т. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tat_savitskaya@tut.by</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aleinikova</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Алейникова</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>aleinikova2004@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Center of Pediatric Oncology, Hematology, and Immunology</institution></aff><aff><institution xml:lang="ru">Республиканский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-09-19" publication-format="electronic"><day>19</day><month>09</month><year>2015</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>34</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2018-09-19"><day>19</day><month>09</month><year>2018</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/109">https://hemoncim.com/jour/article/view/109</self-uri><abstract xml:lang="en"><p>The incidence of methylenetetrahydrofolate reductase ( MTHFR ) gene polymorphism was studied in 97 Belorussian children with acute lymphoblastic leukemia (ALL) treated by the ALL-MB 2002 protocol. It was found that 11 (11.3%) of these patients were homozygous carriers of MTHFR mutant allele 677TT and 14 (14.4%) carried the MTHFR mutant allele 1298CC, which was in line with the incidence of this polymorphism in the European population of children with ALL. Homozygous carriers of MTHFR variant allele 677TT more often developed grade III-IV hepatotoxicity during the consolidation therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Изучена частота встречаемости полиморфизма гена метилентетрагидрофолатредуктазы ( MTHFR ) у 97 детей с острым лимфобластным лейкозом (ОЛЛ), получавших лечение по протоколу ALL-MB 2002. Гомозиготное носительство мутант- ного аллеля гена MTHFR 677ТТ выявлено у 11 (11,3%) пациентов, мутантного аллеля гена MTHFR 1298СС - у 14 (14,4%) пациентов, что соответствует частоте встречаемости данного полиморфизма в европейской популяции детей с ОЛЛ. Установлено, что у гомозиготных носителей вариантного аллеля гена MTHFR 677TT чаще развивалась гепатотоксичность III-IV степени на этапах консолидации ремиссии.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дети</kwd><kwd>острый лимфобластный лейкоз</kwd><kwd>полиморфизм гена MTHFR</kwd><kwd>протокол ALL-MB 2002</kwd><kwd>токсичность</kwd><kwd>children</kwd><kwd>acute lymphoblastic leukemia</kwd><kwd>MTHFR gene polymorphism</kwd><kwd>ALL-MB 2002 protocol</kwd><kwd>toxicity</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Савва НН, Зборовская АА, Алейникова ОВ. Злокачественные новообразова- ния у детей Республики Беларусь: заболеваемость, выживаемость, смерт- ность, паллиативная помощь. 1-е изд. Минск: ГУ РНМБ; 2008</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Румянцева ЮВ, Карачунский АИ, Румянцев АГ. Оптимизация терапии острого лимфобластного лейкоза у детей в России. Педиатрия. Журнал им. ГН Спе- ранского. 2009;88(4):19-27</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Карачунский АИ, Румянцев АГ, Штакельберг А, Самочатова ЕВ, Байдун ЛВ, Хартманн Р. Сравнение протоколов ALL-BFM-90 и ALL-MB-91 для лечения острого лимфобластного лейкоза у детей (предварительные результаты). Педиатрия. Журнал им. ГН Сперанского. 1995;74(2):10-4</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Karachunskiy A, Herold R, von Stackelberg A, Miakova N, Timakow A, Mahortih T, et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia. 2008;22(6):1144-53</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>de Jonge R, Hooijberg JH, van Zelst BD, Jansen G, van Zantwijk CH, Kaspers GJ, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood. 2005;106(2):717-20</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methorexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166-71</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, etal. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer. 2005;65(6):2482-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methylene- tetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy- related toxicity in children treated for acute lymphoblastic leukemia and non- Hodgkin lymphoma. Leuk Lymphoma. 2009;50(6):912-7</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86(8):609-11</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91(8):1113-6</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M, et al. MTHFR polymorphism’s influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res. 2007;31(12):1669-74</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chatzidakis К, Goulas А, Athanassiadou-Piperopoulou F, Fidani L, Koliouskas D, Mirtsou V. Methylenetetrahydrofolate reductase C677T polymorphism: association with risk for childhood acute lymphoblastic leukemia and response during the initial phase of chemotherapy in Greek patients. Pediatr Blood Cancer. 2006; 47(2):147-51</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(11):2525-30</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>te Winkel ML, de Muinck Keizer-Schrama SM, de Jonge R, van Beek RD, van der Sluis IM, Hop WC, et al. Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study. Bone. 2011;48(3):571-7</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22(9):1798-800</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Блохина ЕБ. Роль полиморфизма ферментов цикла фолиевой кислоты (MTHFR, TS) в развитии острого лимфобластного лейкоза. Педиатрия. Журнал им ГН Сперанского. 2004;83(6):67-71</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Блохина ЕБ. Роль генетического полиморфизма в онкологии. Качественная клиническая практика. 2004;1:2-5</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003;3(12):912-20</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Elangovan V, Sekar N, Govindasamy S. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis. Cancer Lett. 1994;87(1):107-13</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy &amp; toxicity with C677T polymorphism of the methylenetet- rahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res. 2006;124(5):521-6</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>de Jonge R, Tissing WJ, Hooijberg JH, Jansen G, Kaspers GJ, Lindemans J, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood. 2009;113(10):2284-9</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Gretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers. 2011; 15(1-2):5-10</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia. 2009;23(5):971-4</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Eloualid A, Abidi O, Charif M, El Houate B, Benrahma H, Louanjli N, et al. Association of the MTHFR A1298C variant with unexplained severe male infertility. PLoS One. 2012;7(3):e34111</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Matsuo K, Hamajima N, Hirai T, Kato T, Inoue M, Takezaki T, et al. Methionine synthase reductase gene A66G polymorphism is associated with risk of colorectal cancer. Asian Pac J Cancer Prev. 2002;3(4):353-59</mixed-citation></ref></ref-list></back></article>
